Date: Sunday, May 17, 2026
Time: 6:30pm
Location: Regency Ballroom TUV
Hyatt Regency
Orlando, FL

Please join expert physicians Dr. Mary Beth Scholand, University of Utah School of Medicine, and Dr. Mark Hamblin, University of Kansas Medical Center for an evening symposium where they will provide a comprehensive review of JASCAYD® (nerandomilast) tablets. During this event, Dr. Hamblin and Dr. Scholand will discuss the safety and efficacy data of JASCAYD and the importance of identifying appropriate patients for treatment.

This presentation is intended for US HCPs only. The FDA-approved indications for JASCAYD® are for the US and may or may not be approved in other jurisdictions. This program was developed by Boehringer Ingelheim Pharmaceuticals and is neither sponsored by nor endorsed by ATS and does not offer CME/CE credit. This evening symposium education program sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. Attendance is limited to healthcare professionals only. Aspects of this program may be reportable under the Physician Payments Sunshine Act. Registration not required. Spaces limited.

(04/26) EM-US-104627